A phase 1 study addressing transthyretin amyloidosis utilized a dosage of 0.3 mg/kg to patients, resulting in the expression of Cas9 and the delivery of its single guide RNA to knock out the transthyretin gene, representing a potential treatment for this disease (Gillmore et al. 2021). Here, TTR is linked to amyloidosis.